Logo (WIPO, 08.03.2022)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke wurde als Bildmarke am 08.03.2022 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Fotografie, Kinematographie, Optik #Kreise #Fotografischer oder kinematografischer Apparat, Projektionsapparat und Laternen #Lupen mit Griff #Kreise mit dunklen Flächen oder Teilen von Flächen
| Markenform | Bildmarke |
| Aktenzeichen | 1682710 |
| Länder | 
|
| Basismarke |
Nr. 97016539,
08. September 2021
|
| Anmeldedatum | 08. März 2022 |
| Ablaufdatum | 08. März 2032 |
Markeninhaber
27 Drydock Avenue, 7th Floor West
Boston MA 02210
US
Boston MA 02210
US
Markenvertreter
250 Vesey Street
New York NY 10281
US
Waren und Dienstleistungen
09
Downloadable computer software for processing, visualizing,
storing and analyzing pre-clinical and clinical radiology
and pathology image data in the fields of drug development
and disease research; downloadable computer software for
image data management purposes, namely, pre-clinical and
clinical image database management and research subject
records management; downloadable computer software for
processing multi-modal imaging data; downloadable computer
software for the processing, storage and analysis of
multi-modal imaging data for quantitation and evaluation of
biomarkers and drug candidates; downloadable software for
the assessment of tumors for research through use of
biomarkers
41
Educational services, namely, developing, arranging and
conducting educational programs, panel discussions and
webinars in the fields of pharmaceuticals, biotechnology,
pre-clinical and clinical trials, and medical research;
educational services, namely, providing non-downloadable
publications, and literature in the fields of
pharmaceuticals, biotechnology, pre-clinical and clinical
trials, and medical research
42
Medical and scientific research, namely, conducting clinical
and pre-clinical trial services for others; pharmaceutical
research and development services; testing of pharmaceutical
pharmacodynamics, pharmacokinetics and efficacy using a
variety of imaging modalities and imaging analysis
platforms; imaging services and pathology in support of
pharmaceutical research and development (term considered too
vague by the International Bureau - Rule 13 (2) (b) of the
Regulations); drug discovery services; conducting early
evaluations in the field of new drugs; scientific
investigations for medical research purposes; medical and
scientific research laboratory services; medical and
scientific research, namely, providing analysis of imaging
data obtained from pre-clinical and clinical trial studies;
medical and scientific research in the fields of medical
radiology imaging, pathology and digital pathology;
providing medical and scientific research information in the
fields of pharmaceuticals and biotechnology; research and
development in the fields of medical imaging,
pharmaceuticals and biotechnology; research services in the
fields of magnetic resonance and molecular imaging; medical
research services, in particular services relating to the
development of radiotherapeutics and drug candidates for
neurodegenerative diseases and precision oncology; design,
development, maintenance and updating of computer software
for image processing, storage and analysis in the fields of
pharmaceuticals and biotechnology; electronic storage of
medical images; processing and analysis of medical images
(term considered too vague by the International Bureau -
Rule 13 (2) (b) of the Regulations); pathology services in
support of drug development; pathology services for
preclinical biomarker discovery research and clinical
trials; hosting of a medical imaging analysis and
visualization platform through a global computer network;
hosting of a database of medical images; software as a
service (SaaS) featuring computer software platforms for
image processing, storage and analysis in the fields of
pharmaceuticals and biotechnology; conducting clinical
trials for others at all stages and in various indications,
particularly in oncology, neurology and systemic diseases;
imaging contract research organization services and
technology solutions, namely, imaging services for medical
and scientific research purposes and technology solutions,
namely, reviewing of radiology images throughout the
clinical trial process and blinded independent central
review of radiology images in the medical research and
clinical trial setting; scientific research services,
namely, integration of imaging results with clinical outcome
data, with application of machine learning and artificial
intelligence applications; development and evaluation of
imaging biomarkers for clinical trial purposes; software
consulting services in the field of drug discovery; cloud
computing featuring software for use in pharmaceutical drug
research in the field of drug discovery; radiochemistry
services; research, development and testing services
relating to radiopharmaceuticals; radiolabeling scientific
research, namely, labeling of both small molecules and
biologics; providing non-downloadable web-based computer
software for database management in the fields of medical
imaging, pharmaceutical and biotechnology research
44
Medical imaging services; medical imaging and radiology
services related to drug development; image analysis and
radiology, namely, analysis of images from all radiological
modalities, such as but not limited to CT, MRI and PET scans
to provide quantitative evaluation of drug candidates
medical radiology, namely, molecular imaging, imaging
utilizing radiopharmaceuticals (term considered too vague by
the International Bureau - Rule 13 (2) (b) of the
Regulations); radiomics, namely, medical radiology services;
medical imaging services, namely, medical imaging and
extraction of imaging biomarkers; pathology services,
namely, testing for research purposes in the fields of
pharmaceuticals and biotechnology (term considered too vague
by the International Bureau - Rule 13 (2) (b) of the
Regulations)
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 29. Juni 2023 | 2023/26 Gaz | JP | Ablehnung |
| 26. April 2023 | 2023/23 Gaz | SG | Ablehnung |
| 15. Februar 2023 | 2023/7 Gaz | CN | Ablehnung |
| 06. Februar 2023 | 2023/6 Gaz | EM | Ablehnung |
| 07. Dezember 2022 | 2022/49 Gaz | GB | Ablehnung |
| 29. November 2022 | 2022/48 Gaz | AU | Ablehnung |
| 08. März 2022 | 2022/35 Gaz | US | Eintragung |
ID: 141682710